Analysis Of Income And Expense [Abstract]

Biocartis Group NV - Filing #3123157

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue from sale of goods	—	—	40,486,000 EUR	—	—	31,893,000 EUR	—	—
Revenue from rendering of services	—	—	1,730,000 EUR	—	—	1,246,000 EUR	—	—
Revenue	—	—	48,269,000 EUR	—	—	43,128,000 EUR	—	—
Material income and expense [abstract]
Research and development expense	—	—	48,054,000 EUR	—	—	45,783,000 EUR	—	—
Finance income (cost)	—	—	8,411,000 EUR	—	—	15,768,000 EUR	—	—
Other finance income (cost)	—	—	1,077,000 EUR	—	—	1,199,000 EUR	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	15,560,000 EUR	—	—	14,618,000 EUR	—	—
Revenue and other operating income	—	—	54,898,000 EUR	—	—	55,559,000 EUR	—	—
Operating expense	—	—	117,543,000 EUR	—	—	102,421,000 EUR	—	—
Sales and marketing expense	—	—	16,763,000 EUR	—	—	15,736,000 EUR	—	—
Expenses by nature [abstract]
Other expenses, by nature	—	—	3,244,000 EUR	—	—	0 EUR	—	—
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method	—	—	659,000 EUR	—	—	532,000 EUR	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	419,000 EUR	71,481,000 EUR	71,481,000 EUR	71,062,000 EUR	63,084,000 EUR	62,945,000 EUR	62,945,000 EUR	139,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	71,481,000 EUR	—	—	62,945,000 EUR	—	—